Experts in the Hot Seat: Precision Therapy with Emerging Cytokine Inhibitors in Asthma

 

Bradley E. Chipps, MD, received his medical degree from the University of Texas Medical Branch in Galveston, Texas. He was a pediatric resident for two years before serving in the Air Force at Ellsworth Air Force Base in South Dakota for two years as a General Pediatrician. He then completed a combined Allergy and Pulmonary Fellowship at Johns Hopkins and spent one year on the faculty in the Pediatric Respiratory Sciences Division.

 

Dr Chipps has been in private practice in Sacramento for 37 years and is Medical Director of Respiratory Therapy and the Cystic Fibrosis Center at Sutter Medical Center in Sacramento, California. He established and is also Associate Medical Director of the Sutter Community Hospitals Sleep Laboratory. Dr Chipps is the Vice President of the American College of Allergy, Asthma & Immunology. He is Board Certified in Pediatric Pulmonology and Allergy and Clinical Immunology.

 

 

 

David M. Lang, MD, serves as Chairman of the Department of Allergy and Clinical Immunology, Co-Director of the Asthma Center, and Director of the Allergy/Immunology Fellowship Training Program in the Respiratory Institute at the Cleveland Clinic. Dr. Lang also teaches Evidence Based Medicine at the Cleveland Clinic Lerner College of Medicine.

 

Dr. Lang received his medical degree from the University of Michigan in Ann Arbor and completed residency training in Internal Medicine at Henry Ford Hospital in Detroit.  Dr. Lang also served an additional year as chief medical resident, prior to pursuing subspecialty training in Allergy and Clinical Immunology at Scripps Clinic and Research Foundation in La Jolla, California.
 
Dr. Lang has carried out a number of research projects, including studies of the epidemiology of urban asthma, drug allergy, anaphylaxis, and chronic urticaria. He has been active in national and regional medical organizations, and has published more than 100 articles in the medical literature. Dr. Lang has been a member of the Joint Practice Parameters Task Force for the specialty of Allergy and Immunology since 2001, and currently serves as Co-Chair of this Task Force. He recently completed a 4-year term on the Board of Directors of the American Academy of Allergy, Asthma and Immunology. He currently serves as Chair of the National Quality Forum Pulmonary and Critical Care Standing Committee and is a member of the National Quality Partners Antibiotic Stewardship Action Team.
 
Dr. Lang has been selected annually as a "Top Doc" in Allergy/Immunology by Cleveland Magazine and as one of the Best Doctors in America for more than a decade.  He currently serves as Deputy Editor for the Journal of Asthma, and is on the Editorial Board of Allergy and Asthma Proceedings; he previously served as Associate Editor and Section Editor of the Annals of Allergy, Asthma, and Immunology.  Dr. Lang received the Hahnemann University Hospital Leadership Award and was the recipient of the Pharmacia Allergy Research Foundation Award at the International College of Allergology and Clinical Immunology meeting in Stockholm.

 
He is board-certified by the American Board of Internal Medicine, the National Board of Medical Examiners, and the American Board of Allergy and Immunology.

Reynold A. Panettieri, Jr, MD, is Director of the Institute for Translational Medicine and Science and Vice Chancellor for Translational Medicine and Science at Rutgers University, and the former Director of the Airways Biology Initiative at the University of Pennsylvania. His interests are in the cellular and molecular mechanisms that regulate airway smooth muscle cell growth and the immunobiology of airway smooth muscle. Consequences of increases in airway smooth muscle growth promote the development of irreversible airflow obstruction and airway remodeling seen in patients with chronic severe asthma. Dr. Panettieri's lab also focuses on cytosolic signaling pathways that mediate gene expression and alter myocyte function.

 

Dr. Panettieri also served as the Deputy Director of the Center of Excellence in Environmental Toxicology at the University of Pennsylvania. He directed the human exposure chamber that defines the molecular mechanisms regulating ozone- and particulate matter-induced airway hyperresponsiveness. In parallel with his basic science interests, Dr. Panettieri managed the comprehensive clinical program for the care of patients with asthma and is actively involved in clinical investigations focused on the management of asthma and COPD.

In addition to his research and clinical interests, Dr. Panettieri served as chairperson of the NIH Lung Cellular, Molecular, and Immunobiology Study Section, is a member of the NIH Distinguished Editorial Panel, and is a member of the American Society for Clinical Investigation and Association of American Physicians.